Aldeyra Therapeutics, Inc.

Initiate enrollment in the Phase 3 TRANQUILITY and TRANQUILITY-2 dry eye trials

Deadline passed; outcome being checked

Announced: 11 Mar 2021
Due: 30 Jun 2021
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“TRANQUILITY and the confirmatory Phase 3 TRANQUILITY-2 Trial are on schedule to initiate enrollment in the first half of 2021.”

SourceAldeyra Therapeutics, Inc. Form 8-K press release, 2021-03-11
FilingSEC filing index
Deadline as statedin the first half of 2021
Deadline used30 Jun 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-ALDX-025636
Cite as https://keptindex.org/c/KI-C-2021-ALDX-025636/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Enrollment start in Phase 3 TRANQUILITY and TRANQUILITY-2 trials
In the company’s control: Medium
Specificity: Medium
Depends on: Regulatory

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-ALDX-025636 · Corrections policy